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Abstract: Specific treatments for the long-life infections by feline leukemia virus (FeLV) and feline
immunodeficiency virus (FIV) are either toxic, expensive or not too effective. Interferon α (IFN-α) is
an immunomodulatory molecule which has been shown in vitro to decrease the release of infective
particles. The aim of this study was to follow the progress of the clinical score and viral parameters
of FeLV- and FIV-naturally infected privately owned cats treated with recombinant human IFN-α
(rHuIFN-α, Roferon-A). Twenty-seven FeLV-infected cats (FeLV+) and 31 FIV-infected cats (FIV+) were
enrolled in the study. Owners were instructed to orally administer 1 mL/day of 60 IU rHuIFN-α/mL
in alternating weeks for four months. Blood samples were taken at the beginning of the study (M0),
mid-treatment (M2), end of treatment (M4), and 6–10 months later (M10). Clinical status at these time
points improved notably with rHuIFN-α treatment, regardless of the initial severity of the disease, an
effect which lasted throughout the study in most animals (15 of the 16 FeLV+ symptomatic cats; 20 of
the 22 FIV+ symptomatic cats) improved markedly their clinical situation. In FeLV+ cats plasma
antigenemia (p27CA), reverse transcriptase (RT) activity, and proviral load decreased at M2 and M4
but increased again at M10 (“rebound effect”). The level of antigenemia or RT activity was below
the detection limits in FIV+ cats, and the effect on proviral load was less marked than in FeLV+ cats.
Taken together, these results indicate that rHuIFN-α is a good candidate for treating FeLV+ cats, but
the “rebound effect” seen when treatment was discontinued suggests that additional studies should
be conducted to clarify its effect on progression of the infection in cats.
Keywords: feline leukemia virus; FeLV; feline immunodeficiency virus; FIV; treatment; interferon;
antigenemia; reverse transcriptase
1. Introduction
Feline leukemia and feline immunodeficiency are two of the most important viral diseases affecting
domestic cats. Though both diseases are produced by the infection of retroviruses (FeLV and FIV,
respectively) which are lifelong persistent, the pathogenesis of each disease is different. FIV infections
have been described to progress following several stages similar to HIV infection in humans, leading
to a final stage with a severe immunodeficiency that predisposes to many secondary infections and,
eventually, to the death of the cat. This final stage of immunodeficiency is reached slowly, due to
the progressive decrease of CD4+ T-cells, for which the virus has tropism. Naturally infected cats
may be infected for many years without evident clinical signs if they live in an adequate environment
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(for example, in a household with appropriate care and food) [1], although recovery from FIV infection
has never been documented. Even though there is a long clinical latency, there is some degree of
FIV replication as antibodies are detectable early after infection and remain during all the life of the
cat [2]. These antibodies are mostly against the main protein of the capsid, p24CA, and their detection
constitutes the basis for serological diagnosis. However, some are triggered also by the envelope
proteins (gp95SU and gp40TM), and their induction is used for a partially successful vaccine [3].
Feline leukemia is considered to be a severe disease that can progress to a fatal illness faster than
FIV infection [4]. FeLV infection results in several different disease outcomes (reviewed in [5]). An
unknown percentage of infected cats can control the infection in the initial stages and avoid the virus
from spreading to target tissues (“abortive infection”). Many cats develop a “regressive infection”, in
which the immune response partially contains the virus and viremia persists only for a few weeks.
In some of these cats, the viremia is longer, and the virus infects haemopoietic stem cells in the bone
marrow, where it can remain latent as proviral DNA integrated in the cellular genome. In approximately
one third of all infected cats, the early immune response is unable to block the virus, and a massive
replication and spread of the virus is produced, including the infection of hematopoietic stem cells
in the bone marrow; this condition is called “progressive infection”, and cats become persistently
viremic. Eventually the infection progresses to the development of related neoplastic (such as leukemia
and lymphoma) and non-neoplastic (such as anemia, gingivostomatitis, and enteritis) diseases [4,6].
Usually, FeLV-infected (FeLV+) cats die within 1 to 3 years after the initial diagnosis due to all the
pathologies and clinical complications the cats develop [5], mostly produced by secondary infections
that may arise because of immunodeficiency. Because of the different outcomes, diagnosis of FeLV
infection is usually complicated for clinicians. During the progressive infection, there is constant
expression of viral proteins, especially of the capsid protein, p27CA, which may not assemble to form
infective viral particles and the excess is secreted into the extracellular environment. Both infective
and non-infective particles may be detected in FeLV infection: infective particles are complete virions
which contain reverse transcriptase (RT), while non-infective particles are empty capsids [7]. Diagnosis
is based on the detection of p27CA, as, unlike FIV-infected (FIV+) cats, antibodies are not as constant,
due in part, to the excess of p27CA, which induces immune anergy which avoids the development of
humoral response and which contributes to the persistence of the virus [8].
Both infections are difficult to treat because (i) antiviral drugs effective against these viruses are
toxic or have significant side effects, (ii) retroviruses perpetuate in infected cells, and (iii) retroviruses
produce a marked deterioration of the immune system, with severe complications and secondary
infections, so the response to therapy in this phase is not as good as expected. For this reason, when
cats are in this immunocompromised stage, the best option is to treat the clinical complications [9].
Several types of therapies have been tested in infected cats with different results: RT inhibitors
(as nucleoside analogues, which are the most widely used), nucleotide synthesis inhibitors, receptor
homologues/antagonists, integrase inhibitors, and interferons (reviewed in [9]).
The use of specific immune modulators, such as interferon, is a good option because they increase
the innate immunity. This is suitable not only to decrease secondary infections which develop in
retrovirosis, but also to decrease viral replication and spread to target cells and organs.
The use of interferons as antiretroviral therapy in cats has been addressed previously [9]. There are
two types of interferon molecules with antiviral properties: type I (IFN-α; IFN-β and IFN-ω) produced
by viral infected cells as first innate immune response against viral infection; and type II (IFN-γ),
produced by T-lymphocytes and NK cells, which stimulates the cell-mediated acquired immunity
against viruses. Type I IFN has been proposed for the treatment of FeLV- and FIV-infected cats based
on previous results in HIV-infected patients [9,10]. Initial studies for treating retrovirus-infected
cats used high doses of recombinant human IFN-α (rHuIFN-α, Roferon-A) administered orally.
Though results were good, these high doses of human IFN stimulated the production of anti-IFN
antibodies [11], and two different alternatives were proposed: prolonged administration of low doses
of rHuIFN-α, and recombinant feline IFN-ω (rFeIFN-ω, Virbagen), which is the only IFN licensed by
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the European Medicines Agency (EMA) specifically for cats. As a molecule active in many cellular
types of different species, rHuIFN-α has several advantages over rFeIFN-ω [12]. The antiviral activity
of IFN-α is well-documented, and has been described to reduce in vitro the amount of viral infective
particles of FeLV and FIV in feline cell cultures, without affecting the synthesis of viral proteins [13,14],
though results in vivo are controversial [15]. In addition, rHuIFN-α is non-toxic, low-cost and easy to
administer orally.
Several studies reported the effect of rHuIFN-α, mainly in FeLV-infected cats (reviewed in [9]).
In general, when this cytokine is administered orally it has a local effect, stimulating the oral and
pharyngeal lymphoid tissue, expanding into an immune cascade that finally has a systemic effect [9].
This has been associated with an improvement in the clinical signs, laboratory alterations and
immunological markers such as the CD4/CD8 ratio of FIV+ or FeLV+ cats treated with IFN-α [10].
However, the effect of this immunomodulatory therapy on viral parameters of retrovirus-infected
cats is not well documented. Contrarily, rFeIFN-ω has been shown to induce minor changes or no
change in the CD4/CD8 ratio, proviral load, viremia and RT activity of infected cats, suggesting that
the overall effect of IFN was on innate immunity [16–18]. Pedretti et al. [19] reported that no significant
differences were observed regarding viral and proviral loads in a group of clinically sick FIV-infected
cats throughout rHuIFN-α treatment.
The aim of the present study was to analyze the progress of viral parameters in FeLV- and
FIV-naturally infected cats during and after treatment with rHuIFN-α, as information is lacking
especially about whether changes in these parameters are long-lasting. This study reflects the everyday
activity of the practitioner, in which when therapy is initiated, it is generally unknown when the animal
became infected, and tries to reproduce the real conditions when treatment is administered by the cat
owners at home.
2. Materials and Methods
2.1. Feline Patients and Administration of Treatment
Twenty-seven FeLV-infected cats (FeLV+) and 31 FIV-infected cats (FIV+) were enrolled in the
study. All were privately owned, though most of them had been stray before. They had all tested
positive to either virus by the serologic Snap Combo Plus (Idexx Laboratories Inc., USA) which detects
FeLV p27CA and antibodies against FIV p24CA, and confirmed as positive by a nested PCR [20], and
no discrepancy had been observed between both sets of results. Cats had been taken by their owners to
one of four private veterinary clinics or to the Veterinary Clinical Hospital (Complutense University of
Madrid), either because they had clinical signs suggestive of feline retrovirosis or for routine controls.
Exclusion criteria included aggressive animals, pregnant and lactating females, or cats with severe
renal, hepatic or cardiac diseases, with neoplasia or in the terminal stages of the disease. Many of the
cats had been recently collected from the street or adopted from a feline community, and this was the
first visit to the clinic. For this reason, the vaccination status was unknown in many cases. They were
all naturally infected and the exact moment of the infection was not known; presumably, the cats were
in different stages of the disease as the study included asymptomatic, with mild disease and with
severe disease cats (see below).
Owners signed an informed consent form for their cat to be included in the study. They agreed not
to treat the cat with any other immunomodulatory drug, but otherwise to care normally for the animal
and not change their usual life habits during the study period (1 year). Animal handling, treatment,
reagent manipulation and data collection were all carried out in compliance with guidelines for Good
Clinical Practice, and Good Laboratory Practice of the Animal Welfare Committee of the Veterinary
Clinical Hospital and the Complutense University, and the experimental procedures were approved by
the Institutional Animal Care and Use Committee of the Complutense University (21 of June, 2007).
One mL doses containing 60 IU of commercial recombinant human interferon alpha 2a
(rHuIFN-α2a, Roferon-A, Roche Diagnostics) were prepared aseptically by diluting the vials with
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sterile saline solution (0.9%), and stored at 4 ◦C until use. Each 1 mL dose was administered orally with
the food or directly in the mouth for 7 consecutive days followed by 7 days of no treatment, alternating
for four months, to a total of 56 doses in four months. Owners were trained as to how to administer
treatment themselves at home, were responsible for administering all doses, and for following the
instructions precisely.
2.2. Clinical Evaluation and Sampling
Owners were requested to take the cat to be examined at four different moments, or visits: M0,
at the beginning of the treatment; M2, in mid treatment or month 2 (±15 days); M4, at the end of
treatment or month 4 (±15 days); M10, four to eight months after finishing the treatment. Data collected
at each visit (M2, M4, M10) were compared to the situation just before treatment was initiated (M0).
The veterinarian in charge in one of the private veterinary practices associated with the study or in the
Veterinary Clinical Hospital of the Veterinary Faculty of Madrid explored clinically and collected blood
from the animals. At each visit, the clinical signs most frequently observed in FeLV and FIV infections
(including loss of appetite, asthenia, altered mucosae, or lymphadenopathy [4]) were rated 0, 1 or 2 [4]
according to their relevance in the disease, and their severity was evaluated in cats to obtain a clinical
score (CS) up to a maximum score of 15 [4]. According to this CS at M0, cats were classified into three
clinical groups (CG): CG1, with no clinical signs (asymptomatic); CG2, with a CS 1–5 (mild disease);
CG3, with a CS ≥ 6 (severe disease).
Blood samples (2 mL) were collected from the cephalic or jugular veins and distributed into a
tube with EDTA and another with heparin-lithium and sent immediately to the Department of Animal
Health of the Veterinary Faculty of Madrid.
2.3. Detection of FeLV p27CA, FIV p24CA and Retrotranscriptase Activity (RT)
The antigenemia was determined by evaluating the concentration of the capsid proteins
FeLV-p27CA and FIV-p24CA in the plasma of the cats diluted 1:2 in PBS, using the commercial
tests PetChek FeLV Antigen Test and PetChek FIV Antigen Test (Idexx), respectively. The amount
of infective viral particles was evaluated by the RT activity of FeLV and FIV as measured by two
tests of Cavidi Tech (Uppsala, Sweden): C-type-RTTM Activity Assay, and Lenti-RTTM Activity Assay,
respectively for FeLV and FIV. Appropriate negative controls and the positive controls included in
the kits were used. Color development was measured in a spectrophotometer (Tecan Spectra-Fluor
A-5082, Crailsheim, Germany), and data were interpreted following the manufacturers’ directions.
2.4. Evaluation of FeLV and FIV Proviral load by Real Time PCR (rtPCR)
Genomic DNA was extracted from whole heparinized blood using DNeasy Tissue Kit (Qiagen),
following the instructions of the manufacturer, and it was stored at −20 ◦C until used. Proviral DNA
was quantified by real-time PCR using previously reported primers and fluorescent probes (0.2 µM)
(Cy5 for FeLV, FAM for FIV) [21,22] in a thermocycler Mx3000P (Agilent Stratagene, USA). Platinum
Taq DNA polymerase (1U/µL) and other PCR reagents were purchased from Biotools, except for the
primers and the fluorescent probes (Genosys-Sigma).
The results of real-time PCR were normalized to cellular glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) using primers GAPDHfor (5´-CGGAGTCAACGGATTTGGTCGTAT-3´) and
GAPDHrev (5´-ACTGAACCTGACCGTACAAGCCTTCTCCATGGTGGTGAAGAC-3´) [23] which
amplify a 307 nucleotide (nt) fragment. GAPDHrev included in its sequence 18 nucleotides (underlined
bold letters), called Z sequence, which is incorporated to the nascent DNA strand, and emits
fluorescence when it combines with Amplifluor™ UniPrimer™ (Merck Millipore). The instructions
of the manufacturer were followed, using 0.5 µM of GAPDHfor and 0.05 µM of GAPDHrev and
1 U/reaction of Titanium Taq DNA polymerase® (Biotools). Results were expressed as the ratio proviral
DNA Ct/total GAPDH Ct. A variation >20% with respect to the value at M0 was considered as decrease
or increase in the viral load.
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The amplifying programs were similar to those described by Leutenegger et al. [21] and Pinches
et al. [22] with slight modifications to allow the joint amplification of proviral genomes and GAPDH,
introducing an elongation step necessary for the UniPrimer system (3 min at 72 ◦C for FeLV rtPCR and
1 min at 72 ◦C for FIV rtPCR). Fluorescence was measured with a FAM filter.
2.5. Statistical Analysis
Results were statistically analyzed by the Informatics Service of the Data Processing Center of
the UCM using Origin Pro 7.5 (https://data.library.virginia.edu/research-software/originpro/), SPSS
(IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY, USA) and
Statgraphics Centurion XVIII Windows (www.statgraphics.com). Differences < 0.05 in the Student’s
t-test (real-time PCR) and Wilcoxon test (CS, p27 and RT activity) were considered significant. Only
significant differences are mentioned in the text.
3. Results
The study involved naturally infected cats with different clinical status, possibly reflecting diverse
stages of the disease. According to the CS when they enrolled the study 11 (40.7%) and 9 (29.0%) of the
FeLV+ and FIV+ cats, respectively, were clinically healthy (CS = 0) and were ascribed to CG1; 8 FeLV+
(29.6%) and 13 FIV+ (41.9%) cats were considered to have mild disease as their CS was 1–5 and were
ascribed to CG2; the remaining 8 (29.6%) of the FeLV+ cats and 9 (29.0%) of the FIV+ cats had a CS
≥ 6 and were considered to have severe disease (CG3). The clinical situation of these cats at M0 has
been published before [4]. Eleven of the FeLV+ and 20 of the FIV+ cats were males. Two thirds of the
FeLV+ (18/27) and FIV+ (21/31) populations were neutered or spayed. Their age ranged between 6
months and 14 years, with FeLV+ being considerably younger (0.3 to 6 years). Most cats were mixed
breed (commonly known as domestic shorthair), while only 7 of the 58 cats were of a breed (4 Persian,
3 Siamese). Though owners had been instructed to bring their cat to all three visits, for different reasons
several failed in this obligation and some data are missing. Only cats which had been brought to at
least two of the three visits were included in the study. Most owners took their cats while treatment
lasted (high fidelity during M2 and M4), but only 44.4% of the FeLV+ and 77.4% of the FIV+ cats were
taken to M10.
During the study period, most of the cats (15 of the 16 FeLV+ symptomatic cats; 20 of the 22 FIV+
symptomatic cats) improved their clinical situation markedly, regardless of their initial clinical status
(Table 1). None of the cats of CG1 (healthy) developed clinical signs during the study. FeLV+ cats
took longer to improve than FIV+ cats, as only 46.6% of them were seen to improve at M2 but 100%
had a better CS at M10 than at M0, while 84.2% of the FIV+ cats had already improved their CS at
M2. Improvement associated with treatment with rHuIFN-α was seen to be statistically significant
(Wilcoxon test) at all three visits: mid-treatment (p < 0.001), end of treatment (p < 0.005) and end
of treatment (p < 0.005). Two FeLV+ and one FIV+ cats died during the study, all of them of CG3.
Improvement was especially noticeable in FeLV+ cats in CG3, as they passed from an average CS
of 7.62 at M0, to 6.0 at M2, 3 at M4 and 0 at M10. The clinical signs which improved the most and
even became unnoticeable in most cats were loss of appetite, asthenia, weight loss and respiratory
alterations. Lymphadenomegaly and oral lesions took longer to resolve.
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Table 1. Progress of the clinical status and of the average of the viral parameters analyzed in FeLV+
cats belonging to clinical group (CG) 1 (asymptomatic), CG2 (mild disease), and CG3 (severe disease)
at the different time points. CS, average clinical score. p27CA, average concentration of FeLV-p27CA
(mg/µL). RT, average RT activity (mU/mL). Proviral load, ratio FeLV Ct: GAPDH Ct. Numbers in
parenthesis are the standard error.
CS p27CA RT Proviral Load
CG1
M0 0.00 (0.00) 0.60 (0.13) 0.86 (0.52) 0.72 (0.04)
M2 0.00 (0.00) 0.49 (0.08) 0.11 (0.09) 0.78 (0.05)
M4 0.00 (0.00) 0.55 (0.18) 0.12 (0.12) 0.88 (0.10)
M10 0.00 (0.00) 0.63 (0.16) 0.65 (0.39) 0.66 (0.06)
CG2
M0 3.50 (0.05) 0.46 (0.13) 1.22 (0.59) 0.61 (0.06)
M2 3.25 (0.84) 0.22 (0.07) 0.28 (0.28) 0.72 (0.06)
M4 1.75 (0.62) 0.40 (0.17) 0.62 (0.40) 0.70 (0.08)
M10 2.00 (0.00) 0.85 (0.19) 3.29 (3.29) 0.77 (0.04)
CG3
M0 8.00 (0.84) 0.49 (0.08) 3.13 (1.46) 0.73 (0.06)
M2 6.17 (1.48) 0.58 (0.16) 2.51 (1.55) 0.81 (0.07)
M4 3.00 (1.91) 0.20 (0.10) 0.25 (0.15) 0.88 (0.04)
M10 0.00 (0.00) 0.66 (0.40) 0.40 (0.37) 0.69 (0.03)
3.1. Plasma Antigenemia
The capsid protein of FIV, p24CA, was not detected in any of the sera of cats. Contrarily,
FeLV-p27CA, was detected in all the FeLV+ cats. When compared to M0, the concentration of p27CA
decreased in 60.0% of the cats at M2, and in 59.1% at M4, but increased in 32.0% and 27.3% of FeLV+
cats at M2 and M4, respectively. However, at M10 66.7% of these animals had a higher concentration
of p27CA than at M0 (Figure 1A). In addition, when compared to M0 the average concentration
of FeLV-p27CA decreased 18.1% and 23.6% at M2 and M4, respectively, increasing 31.5% at M10
(Figure 2A). Thus, a “rebound pattern” was observed in interferon-treated FeLV+ cats. Surprisingly,
the highest average value of p27CA at M0 was in the group of healthy cats (CG1), but the initial
values of p27CA were similar in all CG (0.46−0.60 mg/µL). However, the percentage of cats in which
FeLV-p27CA was reduced at M2 when compared to M0 was higher in CG1 and CG2 (70.0% and 75.0%,
respectively), than in CG3 (28.6%) (p < 0.05).
3.2. Reverse Transcriptase (RT) Activity
As with the capsid protein, RT activity was not detected in FIV+ cats. On the other hand, the RT
activity was detectable in 66.6%, 28.0%, 31.8%, and 58.3% of the treated FeLV+ cats at M0, M2, M4 and
M10, respectively. Around three fourths of the cats that had a positive RT activity value at M0 had a
decreased reading at M2 and M4, but a much smaller percentage had an improved RT activity value at
M10 (Figure 1C). In addition, the detection of RT activity increased progressively in cats in which it
was initially undetectable (Figure 1D). The highest improvement on the RT activity of treated FeLV+
cats was observed at M2, when the highest percentage of these cats had undetectable levels of this
parameter. However, the concentration of RT activity was the lowest at M4, over 95% lower than at
M0, increasing when treatment was discontinued (Figure 2B). All these results support the “rebound
pattern” mentioned above. No significant differences were observed in the progress of RT activity in
relation to clinical status at M0.
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Figure 1. Progress in peripheral blood of rHuIFN-α-treated cats of FeLV-p27CA (A), proviral load in
FeLV+ cats (B), FeLV-RT in cats with detectable levels of this parameter at M0 (C) and undetectable
levels at M0 (D), and proviral load in FIV+ cats (E). Each column represents the number of cats
(including the percentage) in which the parameter studied at M2, M4 or M10 was >20% better (green)
or worse (red) than the respective value at M0. White sections represent the number of cats in which
the value was <20% better or worse than that detected at M0.
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Figure 2. Progress of FeLV-p27CA (A) and RT activity (B) in plasma of FeLV+ cats treated with
rHuIFN-α. Columns show how much the average concentration of p27CA or RT activity had increased
or decreased as compared to the average at M0; line indicates the average concentration of p27CA
(mg/µL) or RT activity (mU/mL) at each time point; bars in line indicate standard error. Note the
favorable progress of cats at M2 and M4, and the unfavorable progress at M10.
3.3. Proviral Load
The proviral load was quantified in the peripheral blood of FeLV+ and FIV+ cats using real time
PCR to determine how it varied with treatment. As explained in the Material and Methods section,
values were considered to increase or decrease when the percentage of provirus/GAPDH varied by
more than 20% with respect to the value at M0.
As with the other tests, in FeLV+ cats there was an improvement of proviral load at M2 and M4
when compared to M0 (40.0% and 59.1% decrease, respectively), but a regression at M10 (33.3% decrease
compared to M0) (Figure 1B). The percentage of cats that increased their proviral load remained stable
throughout the study (16.0% at M2, 13.6% at M4 and 16.7% M10) (Figure 1B). In addition, the lowest
average proviral load was at M4, 19.8% lower than at M0. There was a positive correlation between
the concentration of FeLV-p27CA protein and proviral load (p < 0.05). No significant differences were
observed in the evolution of the proviral load in the different clinical groups, but female cats had
increased FeLV proviral loads between M0 and M4, while male cats did not (p < 0.05).
The effect of rHuIFN-α on the proviral load was notably less in FIV+ cats than on FeLV+ cats
(Figure 1E). Proviral load decreased in 29.2% of the FIV+ cats at M2 (vs. 40.0% of the FeLV+ cats at
M2). At the following visits, the percentage of cats with decreased proviral load was less than at M2
(15.4% and 8.3% at M4 and M10, respectively). On the other hand, the percentage of cats in which
proviral load increased was also lower than the corresponding values in FeLV+ cats (no cats in M2,
one in M4 and two at M8).
3.4. Combined Results of the Viral Parameters in FeLV+ Cats
Results obtained with cats included in the same clinical group were compared in order to better
understand the viral progression depending on the clinical status (Table 1). Few differences were
observed throughout the study in the concentration of FeLV-p27CA, RT activity, or proviral load
between the three different clinical groups, though the starting RT activity was highest in cats of CG3
(severe disease), and improved the most in this group.
With regard to the progress of the viral parameters studied, the highest percentage of cats which
improved their values was between M2 and M4. M4 was the visit in which the average FeLV-p27CA, RT
and proviral load was the most reduced when compared to M0 (23.6%, 96.2% and 19.8%, respectively)
Viruses 2019, 11, 845 9 of 13
which seems to indicate that it corresponds to the highest response to treatment (Table 1). At M10 the
number of animals with a favorable progress was drastically reduced.
4. Discussion
This study was conducted to analyze the effect of oral treatment with low doses of rHuIFN-α
(Roferon-A) on the viral parameters of domestic cats naturally infected with FeLV or FIV, since from
our previous experience, we had observed that the clinical status of infected cats improved notably
with IFN treatment. The results show that treatment with low doses of rHuIFN-α was associated with
an improvement of the viral parameters studied in FeLV+ cats as long as the animals were treated,
but reverted to levels similar to the original ones within 4–8 months upon treatment discontinuation
(“rebound effect”). Contrarily, in most animals, the clinical status improved steadily throughout the
one-year study.
An important aspect of this study is that it represents what practitioners find at the clinic. They
do not usually know when the cat was infected, the stage of the disease, the immune status of the
animal, the CD4/CD8 ratio or the proviral load. Cats may have one or more clinical signs or be totally
asymptomatic. Treatment with IFN may produce unexpected results, ranging from no visible effects to
an apparent clinical improvement. A big concern for the veterinary practitioner is whether clinical
improvement correlates with a true improvement of the infection, i.e., a decrease in viremia or the
proviral load of the cat, or whether the infection may revert when IFN treatment is discontinued.
In this type of study, average values are not easy to use, as they do not provide a true measure of
the progress in each cat. Thus, a single-arm clinical study was applied, similarly to other previously
published studies with naturally infected cats [17,18,24]. We agree with Gil et al. [17], who suggest
that values at D0 are potentially more representative than a placebo in studies in field conditions, in
which animals have been infected at unknown moments. Therefore, each cat at day 0 was considered
its best untreated control, and the response to treatment was evaluated over time by comparing each
parameter in each individual cat at each visit with their situation before beginning treatment (M0).
This eliminated the need to use a placebo-treated or non-treated group of cats, which would have been
ethically controversial, as owners demand a solution for their cats [17,18,24]. The control group would
ultimately be necessary if we were studying experimentally infected animals, where all cats should be
in the same stage of infection with the same viral strain. In our study, we had a heterogeneous group
of cats and it was impossible to know the point and stage of the infection in each animal.
Capsid protein or RT activities were easily measured in the plasma of FeLV+ cats. FeLV-p27CA
may be released by infected cells not associated with viral particles and is thus used as a marker of
antigenemia [13,25,26], while RT is present only inside virions and is proportional to the number of
infective viral particles [7]. Thus, the follow-up of both proteins provides information on the progress
of FeLV in infected cats treated with rHuIFN-α.
Around 60–75% of FeLV+ cats had improved FeLV-p27CA and FeLV-RT activity during M2 and
M4 of treatment. This suggests that rHuIFN-α decreases antigenemia and circulating infective particles.
Similar results with respect to the concentration of p27CA in blood had been obtained previously [11],
and also agree with previous data which suggest that p27CA level is an indicator for the outcome of
the FeLV-infection and may differentiate between regressive and progressive infections [27]. According
to our results, rHuIFN-α had a more evident effect on RT activity than on p27CA, as the average value
of RT activity decreased more and in a higher percentage of animals than that of p27CA. This supports
the observation that interferon acts on the assembly and formation of viral particles more than on the
expression of viral proteins, as was derived from previous in vitro studies [13,28]. Affecting this step
and not the protein synthesis, p27CA may be released, explaining why the plasma concentration of
p27CA decreased less than the RT activity.
The presence of high levels of p27CA in FeLV+ cats is associated with the final progressive
stages of this infection [25], and in fact, this parameter has been used to follow the progress of the
infection upon treatment [27]. In agreement with the European Pharmacopoeia, a cat is designated as
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progressively infected when FeLV-p27CA is positive for three consecutive weeks [27]. Thus, low p27CA
concentration in plasma may mean a positive effect of rHuIFN-α treatment, similarly to what happens
in HIV patients, in which the decrease of circulating p24CA levels induced by IFN-α correlates with
the increase of CD4+ T-cells and an antitumoral response against Kaposi’s sarcoma [29]. However, it is
important to mention that in our study, rHuIFN-α drastically improved the clinical score of all animals,
which did not result in a rebound effect during the period that the study lasted. Thus, in our study
there was no correlation between the clinical and the viral status after treatment was discontinued.
In this sense, our results agree with observations by others who indicated a lack of correlation between
viremia and clinical scores in naturally FIV-infected cats [18].
The study of the proviral load in retroviral infections provides information about the number
of infected cells, and thus, the progress of the infection and also the ability of the cat to transmit the
infection. In the case of FeLV+ cats treated with rHuIFN-α, our results show that at M4 59.1% of them
had a decreased proviral load as compared to M0. However, the percentage decreased to 33.3% at
M10, suggesting that, as with other parameters, the effect of rHuIFN-α ceased when treatment was
discontinued. In general, the effect of rHuIFN-α on proviral load was not as positive as on RT activity
or p27CA protein. All these results are slightly better than those reported for rFeIFN-ω (Virbagen), as
no substantial improvement of the proviral load had been observed in FeLV+ or FIV+ Virbagen-treated
cats [16], or even the proviral load had increased in FIV+ cats after subcutaneous administration of this
molecule [18].
The concentration of p27CA and RT activity and proviral load in plasma experimented a “rebound
pattern” at M10 in FeLV+ cats. These results seem to indicate that the effect of rHuIFN-α was reduced
after discontinuing treatment, and agree with our observations on biopathological parameters in these
cats (manuscript in preparation). Zeidner et al. [11] described the decrease of the concentration of
p27CA at the beginning of treatment with rHuIFN-α, followed by its increase at the end, similarly
to our results. However, these authors detected the presence of anti-rHuIFN-α specific antibodies,
which could have blocked its effect. A rebound effect in viremia was also observed after a short-term
treatment with an integrase inhibitor drug in FeLV infected cats [27]. According to our results, the viral
situation of FeLV+ cats was worse in 16% to 67% at M10 than at M0, even in those infected cats which
initially had undetectable levels of RT activity. This could mean that upon the discontinuation of
treatment, FeLV+ cats could experience a worsening of the viral parameters, usually along with anemia,
and life expectancy could be short. The possibility of a longer treatment with rHuIFN-α, not explored
so far to the best of our knowledge, should be addressed in future studies.
Treatment with rHuIFN-α had a much lesser effect on FIV-infected cats. Though both FIV-p24CA
and FIV-RT activity could be detected in in vitro studies [14], no FIV p24CA or RT activity was detected
in the plasma of FIV+ cats. Several reasons could account for this. First, the virus may be latent, and
not be expressed to a high degree [30,31]. However, around two thirds of the animals had clinical
signs at the beginning of the study, which would indicate an active infection. A second possibility
could be that circulating antibodies against FIV, which are undoubtedly present as they are detected by
the Idexx device, could block free virus in blood [32], though this possibility would not explain the
absence of RT activity in the blood samples. However, the most likely explanation is that cats were not
in the short antigenemia window, as FIV is mostly inside cells and antigenemia or presence of viral
particles in plasma is transient and not maintained [33]. Other authors have pointed out the difficulty
in detecting viremia in cats naturally infected with FIV with an unknown duration of infection [18].
The proviral load of a very high percentage (70–83%) of FIV+ cats treated with rHuIFN-α was
not modified and values were similar to those at M0, suggesting that treatment does not evidently
improve this parameter. Contrarily to our results, a study by Pedretti et al. [19] evidenced the decrease
in the proviral load in sick FIV+ cats (possibly similar to CG3 cats of our study), both in placebo- and
in rHuIFN-α-treated cats, and no significant differences were observed between both groups.
Previously, it has been proposed that direct antiviral effects were unlikely after oral administration
of rHuIFN-α, and that its action could be related to an indirect effect through the stimulation of
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local lymphoid tissue in the oral cavity that triggers an immune response against viruses (reviewed
in [9]). However, the results presented in this paper suggest that oral rHuIFN-α does seem to have an
effect on the viral parameters studied, also corroborating in vitro studies published by our group [13].
A possible drawback of our study could be the production of antibodies against human IFN, which
has been demonstrated to happen by treating with high doses of this cytokine [11]. However, at the
doses and administration route used in this study (60 IU rHuIFN-α/day/cat orally) we did not detect
the presence of specific antibodies at any of the samples collected (results not shown).
With respect to other antiviral treatments, rHuIFN-α has the advantage of having no side effects
or toxicity and not developing drug-resistant strains of virus, as described in treatments with antiviral
drugs (such as AZT, which induces non-regenerative anemia, reviewed in [9,34]). Other advantages
are the easy availability and low cost of this cytokine, and the possibility of per os administration.
In addition, most antivirals used in cats are less effective against FeLV, as these drugs are specifically
targeted for HIV in humans, and are more related to FIV (and their enzymes have similar sensitivities
to inhibitors). There are several data that show a real effect of antivirals in infected cats, and in many
of these compounds and similar to our results, the positive effect disappears after the treatment is
stopped (reviewed in [9]).
The study had several limitations. One of these was including cats at different stages of the
infection. Another was that the results were dependent on the adherence of the cat owners to the
treatment administration and taking the cat to the clinician at the appointed times. As owners possibly
judge the progress of the infection by the presence or absence of clinical signs that they can observe,
some may have relaxed in their duty of administering some of the doses of treatment upon considering
that the cat had improved clinically. Additionally, M10 was the visit at which the fewest cats were
taken to the veterinary practice, which could be due to owners’ negligence, a long-lasting improvement,
or dramatic impoverishment of the clinical situation of the cat. As a whole, these events which
depended on the owner were impossible to control. Nevertheless, these limitations do not decrease
the relevance of the results presented and, as mentioned above, they more accurately represent the
situation encountered by the clinician at the everyday practice. Lastly, the fact that PCR to determine
the proviral load was done on heparinized blood, instead of using blood conserved in EDTA or sodium
citrate, may have decreased the values obtained, as heparin may block Taq polymerase [35]. However,
the use of normalized values compared to GAPDH, a housekeeping gene, may have diminished the
importance of this limitation; in addition, previously we had compared results using blood collected
on heparin or on EDTA tubes and found no measurable variations.
5. Conclusions
When used in FeLV- or FIV-naturally infected cats, oral treatment with rHuIFN-αmay cause an
improvement in the antigenemia (p27CA) and RT activity and proviral load in FeLV+ cats, while it
possibly affects viral parameters in FIV+ cats to a lesser extent. Taking into account the results in
the viral parameters and the clinical improvement, the oral treatment with rHuIFN-α could be an
interesting alternative for the therapy of cats infected with FeLV and FIV, mainly due to its low toxicity,
the low cost of these compound, and the ease of its oral administration compared to the injectable
protocol for other compounds, which facilitates its supply by the owner at home. The reversion to initial
values of several of the factors studied after treatment was discontinued suggests that treatment with
rHuIFN-α had not been as long as necessary, or maybe that cycles should be repeated to consolidate
the improvement. More studies are necessary to determine whether the rebound pattern is a natural
progress of the infection, or whether it may be mitigated by longer treatment.
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